Feasibility of intra-arterial chemotherapy followed by chemoembolization, every 28 days, in unresectable hepatocellular carcinoma

Marco Colleoni, Guido Liessi, Giorgio Mastrapasqua, Patrizia Nelli, Giovanni Vicario, Gigliola Sgarbossa, Francesca Pancheri, Paolo Manente

Research output: Contribution to journalArticle

Abstract

Encouraging response rates and survival have been reported with intra- arterial (i.a.) chemotherapy and chemoembolization, but limited data are available on the association of the two treatment modalities. We therefore started a feasibility study of i.a. chemotherapy plus chemoembolization, performed every 28 days for 3 cycles, according to the following schedule: L-leucovorin (100 mg/m 2 i.v.), fluorouracil (800 mg/m 2 i.a.), and carboplatin (250 mg/m 2 i.a.). Chemoembolization with mitoxantrone (10 mg/m 2) plus ethiodized oil was performed immediately after this treatment, followed by gelatin powder. Fourteen patients entered the study and were evaluable for side effects. Main patient characteristics were: males 13, females 1; median age 65 yr (range 45-75); stage TNM II-III 10, IVA 4; Childs' A 8, Childs' B 6; elevated baseline α-fetoprotein, 11; cirrhosis 14. No drug-related deaths have been observed. Ten patients were able to complete the program. The reasons for discontinuing treatment were worsening of liver functions in 3 cases and grade IV neutropenia in 1 patient. Eight patients had grade I-II pain and 10 patients had grade I-II fever. In conclusion the study demonstrated that chemoembolization plus i.a. chemotherapy is feasible in patients with hepatocellular carcinoma in cirrhosis and deserves further investigation.

Original languageEnglish
Pages (from-to)879-882
Number of pages4
JournalOncology Reports
Volume3
Issue number5
Publication statusPublished - Sep 1996

Fingerprint

Hepatocellular Carcinoma
Drug Therapy
Fibrosis
Fetal Proteins
Ethiodized Oil
Mitoxantrone
Leucovorin
Carboplatin
Feasibility Studies
Gelatin
Neutropenia
Fluorouracil
Powders
Appointments and Schedules
Fever
Therapeutics
Survival Rate
Pain
Liver
Pharmaceutical Preparations

Keywords

  • chemoembolization
  • hepatocellular carcinoma
  • intra-arterial chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Colleoni, M., Liessi, G., Mastrapasqua, G., Nelli, P., Vicario, G., Sgarbossa, G., ... Manente, P. (1996). Feasibility of intra-arterial chemotherapy followed by chemoembolization, every 28 days, in unresectable hepatocellular carcinoma. Oncology Reports, 3(5), 879-882.

Feasibility of intra-arterial chemotherapy followed by chemoembolization, every 28 days, in unresectable hepatocellular carcinoma. / Colleoni, Marco; Liessi, Guido; Mastrapasqua, Giorgio; Nelli, Patrizia; Vicario, Giovanni; Sgarbossa, Gigliola; Pancheri, Francesca; Manente, Paolo.

In: Oncology Reports, Vol. 3, No. 5, 09.1996, p. 879-882.

Research output: Contribution to journalArticle

Colleoni, M, Liessi, G, Mastrapasqua, G, Nelli, P, Vicario, G, Sgarbossa, G, Pancheri, F & Manente, P 1996, 'Feasibility of intra-arterial chemotherapy followed by chemoembolization, every 28 days, in unresectable hepatocellular carcinoma', Oncology Reports, vol. 3, no. 5, pp. 879-882.
Colleoni, Marco ; Liessi, Guido ; Mastrapasqua, Giorgio ; Nelli, Patrizia ; Vicario, Giovanni ; Sgarbossa, Gigliola ; Pancheri, Francesca ; Manente, Paolo. / Feasibility of intra-arterial chemotherapy followed by chemoembolization, every 28 days, in unresectable hepatocellular carcinoma. In: Oncology Reports. 1996 ; Vol. 3, No. 5. pp. 879-882.
@article{2d6e29b7ac2f4071852b1de00462ce75,
title = "Feasibility of intra-arterial chemotherapy followed by chemoembolization, every 28 days, in unresectable hepatocellular carcinoma",
abstract = "Encouraging response rates and survival have been reported with intra- arterial (i.a.) chemotherapy and chemoembolization, but limited data are available on the association of the two treatment modalities. We therefore started a feasibility study of i.a. chemotherapy plus chemoembolization, performed every 28 days for 3 cycles, according to the following schedule: L-leucovorin (100 mg/m 2 i.v.), fluorouracil (800 mg/m 2 i.a.), and carboplatin (250 mg/m 2 i.a.). Chemoembolization with mitoxantrone (10 mg/m 2) plus ethiodized oil was performed immediately after this treatment, followed by gelatin powder. Fourteen patients entered the study and were evaluable for side effects. Main patient characteristics were: males 13, females 1; median age 65 yr (range 45-75); stage TNM II-III 10, IVA 4; Childs' A 8, Childs' B 6; elevated baseline α-fetoprotein, 11; cirrhosis 14. No drug-related deaths have been observed. Ten patients were able to complete the program. The reasons for discontinuing treatment were worsening of liver functions in 3 cases and grade IV neutropenia in 1 patient. Eight patients had grade I-II pain and 10 patients had grade I-II fever. In conclusion the study demonstrated that chemoembolization plus i.a. chemotherapy is feasible in patients with hepatocellular carcinoma in cirrhosis and deserves further investigation.",
keywords = "chemoembolization, hepatocellular carcinoma, intra-arterial chemotherapy",
author = "Marco Colleoni and Guido Liessi and Giorgio Mastrapasqua and Patrizia Nelli and Giovanni Vicario and Gigliola Sgarbossa and Francesca Pancheri and Paolo Manente",
year = "1996",
month = "9",
language = "English",
volume = "3",
pages = "879--882",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Feasibility of intra-arterial chemotherapy followed by chemoembolization, every 28 days, in unresectable hepatocellular carcinoma

AU - Colleoni, Marco

AU - Liessi, Guido

AU - Mastrapasqua, Giorgio

AU - Nelli, Patrizia

AU - Vicario, Giovanni

AU - Sgarbossa, Gigliola

AU - Pancheri, Francesca

AU - Manente, Paolo

PY - 1996/9

Y1 - 1996/9

N2 - Encouraging response rates and survival have been reported with intra- arterial (i.a.) chemotherapy and chemoembolization, but limited data are available on the association of the two treatment modalities. We therefore started a feasibility study of i.a. chemotherapy plus chemoembolization, performed every 28 days for 3 cycles, according to the following schedule: L-leucovorin (100 mg/m 2 i.v.), fluorouracil (800 mg/m 2 i.a.), and carboplatin (250 mg/m 2 i.a.). Chemoembolization with mitoxantrone (10 mg/m 2) plus ethiodized oil was performed immediately after this treatment, followed by gelatin powder. Fourteen patients entered the study and were evaluable for side effects. Main patient characteristics were: males 13, females 1; median age 65 yr (range 45-75); stage TNM II-III 10, IVA 4; Childs' A 8, Childs' B 6; elevated baseline α-fetoprotein, 11; cirrhosis 14. No drug-related deaths have been observed. Ten patients were able to complete the program. The reasons for discontinuing treatment were worsening of liver functions in 3 cases and grade IV neutropenia in 1 patient. Eight patients had grade I-II pain and 10 patients had grade I-II fever. In conclusion the study demonstrated that chemoembolization plus i.a. chemotherapy is feasible in patients with hepatocellular carcinoma in cirrhosis and deserves further investigation.

AB - Encouraging response rates and survival have been reported with intra- arterial (i.a.) chemotherapy and chemoembolization, but limited data are available on the association of the two treatment modalities. We therefore started a feasibility study of i.a. chemotherapy plus chemoembolization, performed every 28 days for 3 cycles, according to the following schedule: L-leucovorin (100 mg/m 2 i.v.), fluorouracil (800 mg/m 2 i.a.), and carboplatin (250 mg/m 2 i.a.). Chemoembolization with mitoxantrone (10 mg/m 2) plus ethiodized oil was performed immediately after this treatment, followed by gelatin powder. Fourteen patients entered the study and were evaluable for side effects. Main patient characteristics were: males 13, females 1; median age 65 yr (range 45-75); stage TNM II-III 10, IVA 4; Childs' A 8, Childs' B 6; elevated baseline α-fetoprotein, 11; cirrhosis 14. No drug-related deaths have been observed. Ten patients were able to complete the program. The reasons for discontinuing treatment were worsening of liver functions in 3 cases and grade IV neutropenia in 1 patient. Eight patients had grade I-II pain and 10 patients had grade I-II fever. In conclusion the study demonstrated that chemoembolization plus i.a. chemotherapy is feasible in patients with hepatocellular carcinoma in cirrhosis and deserves further investigation.

KW - chemoembolization

KW - hepatocellular carcinoma

KW - intra-arterial chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029787817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029787817&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 879

EP - 882

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -